Citigroup’s Creative Medical Technology CELZ Stock Holding History

Citigroup’s Portfolio CELZ Stock Details CELZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-665	Closed	-$5K	–	5872
2022 Q2	$5K	Sell	665 -551	-45%	-$8.88K	﹤0.01%	5601
2022 Q1	$47K	Buy	+1,216	New	+$27.1K	﹤0.01%	4749

Other funds holding CELZ

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Citigroup's CELZ Position: Q3 2022 in Review

Citigroup sold out of Creative Medical Technology (CELZ) in Q3 2022, closing a stake of 665 shares — an estimated $5K sold.

Citigroup first reported a position in CELZ in Q1 2022 and held it in 2 quarters. The position peaked at $47K in Q1 2022. 17 funds tracked by Wall St. Rank hold CELZ as of Q3 2022.

Citigroup reported no remaining Creative Medical Technology position as of Q3 2022 after selling out during the quarter.
Citigroup sold 665 Creative Medical Technology shares in Q3 2022, an estimated $5K.
Citigroup first reported a position in Creative Medical Technology in Q1 2022 and held it in 2 quarters.
Citigroup's Creative Medical Technology position peaked at $47K in Q1 2022.
17 funds tracked by Wall St. Rank held Creative Medical Technology as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.